MedTrace Logo

Study of SI000413 in Knee Osteoarthritis Patients

NCT01525758 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2013-08-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy and safety of SI000413 in patients with knee osteoarthritis by orally administration and to determine optimal dose.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

SI000413

1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks

DRUG

microcrystalline cellulose

identical number of tablets to active drug groups

Sponsors & Collaborators

  • Dong-A Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yoon-Jae Cho, MD · Kyunghee University Medical Center

  • Myung-Chul Lee, MD · Seoul National University Hospital

  • We-Yeon Won, MD · Ajou University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01525758 on ClinicalTrials.gov